| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10924434 | Seminars in Oncology | 2013 | 8 Pages |
Abstract
The introduction of therapy targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapomycin (mTOR) has significantly improved the outcome of patients with metastatic renal cancer. In this article a comprehensive overview of treatment choices for previously untreated patients with metastatic disease is given. Both established and emerging therapeutic options are discussed, as are prognostic factors predicting outcome.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ana M. Molina, Robert J. Motzer, Daniel Y. Heng,